Ablynx NV Aktie [WKN DE: A0M7H2 / ISIN: BE0003877942]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ablynx NV

16.10.17		PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
16.10.17		ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER (GlobeNewswire)
13.10.17		PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
06.10.17		PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
02.10.17		ABLYNX FILES REGISTRATION STATEMENT FOR A PROPOSED GLOBAL OFFERING (GlobeNewswire)
02.10.17		ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP (GlobeNewswire)
14.09.17		ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
07.09.17		ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON (GlobeNewswire)
30.08.17		PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
30.08.17		PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
24.08.17		ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE (GlobeNewswire)
17.08.17		ABLYNX WILL ANNOUNCE ITS 2017 HALF YEAR RESULTS WITH WEBCAST ON 24 AUGUST 2017 (GlobeNewswire)
11.08.17		ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
26.07.17		ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP (GlobeNewswire)
24.07.17		ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
20.07.17		ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES (GlobeNewswire)
17.07.17		ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR (GlobeNewswire)
23.12.16		FMR LLC ANNOUNCE 9.16% SHAREHOLDING IN ABLYNX (GlobeNewswire)
30.11.16		ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK (GlobeNewswire)
23.11.16		ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2016 AND A YEAR-TO-DATE BUSINESS UPDATE (GlobeNewswire)
18.11.16		FMR LLC ANNOUNCE 9.10% SHAREHOLDING IN ABLYNX (GlobeNewswire)
10.11.16		ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
09.11.16		ABLYNX TO PRESENT AT THE JEFFERIES LONDON HEALTHCARE CONFERENCE 2016 (GlobeNewswire)
21.10.16		ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
20.10.16		ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS (GlobeNewswire)
12.10.16		ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC. (GlobeNewswire)
11.10.16		FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX (GlobeNewswire)
10.10.16		ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP (GlobeNewswire)
29.09.16		ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP (GlobeNewswire)
15.09.16		ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC. (GlobeNewswire)
06.09.16		ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM GAM HOLDING AG, GAM INTERNATIONAL MANAGEMENT LIMITED AND TAUBE HODSON STONEX PARTNERS LLP (GlobeNewswire)
25.08.16		ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE (GlobeNewswire)
17.08.16		ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016 (GlobeNewswire)
12.08.16		ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V. (GlobeNewswire)
09.08.16		ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, CONFIRMING ITS BEST-IN-CLASS POTENTIAL (GlobeNewswire)
04.08.16		BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX (GlobeNewswire)
20.07.16		ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
07.07.16		ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA (GlobeNewswire)
16.06.16		CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX (GlobeNewswire)
16.06.16		VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX (GlobeNewswire)
14.06.16		PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
10.06.16		PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
03.06.16		ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016 (GlobeNewswire)
26.05.16		ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION (GlobeNewswire)
13.05.16		PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW") (GlobeNewswire)
12.05.16		ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE (GlobeNewswire)
03.05.16		ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS HOSPITALISED WITH AN RSV INFECTION (GlobeNewswire)
29.04.16		ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION (GlobeNewswire)
22.04.16		ABLYNX ANNOUNCES WARRANT EXERCISE (GlobeNewswire)
21.04.16		ABLYNX TO RECEIVE AN €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY (GlobeNewswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Tesla-Aktie erneut mit massivem Minus: Abwärtstrend setzt sich fort

Kräftige Talfahrt an den US-Börsen -- ATX und DAX schließen tief im Minus -- Asiens Börsen letztlich uneinheitlich

Daten zu Abnehmmittel drücken auf Novo Nordisk-Aktie

Anleger setzen auf Rüstung - Aktien von Rheinmetall, RENK & HENSOLDT im Plus

Droht der Tesla-Aktie der Absturz? Experte sieht hohes Risiko - auch wegen Elon Musk

Alternative KI-Aktien: Die neuen Top-Picks abseits der Magnificent 7 wie NVIDIA & Co.

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.03.2025 20:41
Kaufwert:	EUR
	Hinzufügen Speichern